Healthcare provider profile · identity verified

Odette Mcbride

Nurse Practitioner · HOMESTEAD, FL · NPI 1609248475

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	518	172
Losartan Potassium	Losartan Potassium	317	99
Metformin Hcl	Metformin Hcl	294	85
Amlodipine Besylate	Amlodipine Besylate	282	81
Gabapentin	Gabapentin	255	57
Lisinopril	Lisinopril	218	65
Levothyroxine Sodium	Levothyroxine Sodium	171	48
Hydrochlorothiazide	Hydrochlorothiazide	159	54
Eliquis	Apixaban	150	29
Famotidine	Famotidine	147	52
Rosuvastatin Calcium	Rosuvastatin Calcium	143	46
Albuterol Sulfate Hfa	Albuterol Sulfate	132	47
Metoprolol Succinate	Metoprolol Succinate	128	41
Omeprazole	Omeprazole	126	53
Fluticasone Propionate	Fluticasone Propionate	116	52
Metoprolol Tartrate	Metoprolol Tartrate	107	25
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	105	24
Furosemide	Furosemide	99	32
Januvia	Sitagliptin Phosphate	99	24
Tamsulosin Hcl	Tamsulosin Hcl	99	36
Simvastatin	Simvastatin	95	32
Glipizide	Glipizide	94	28
Escitalopram Oxalate	Escitalopram Oxalate	90	25
Diclofenac Sodium	Diclofenac Sodium	81	43
Sildenafil Citrate	Sildenafil Citrate	80	13
Azithromycin	Azithromycin	75	62
Alendronate Sodium	Alendronate Sodium	72	24
Hydralazine Hcl	Hydralazine Hcl	64	12
Nifedipine Er	Nifedipine	64	15
Pantoprazole Sodium	Pantoprazole Sodium	64	24
Carvedilol	Carvedilol	57	22
Vitamin D2	Ergocalciferol (Vitamin D2)	57	28
Farxiga	Dapagliflozin Propanediol	55	12
Allopurinol	Allopurinol	54	suppressed
Metformin Hcl Er	Metformin Hcl	54	15
Montelukast Sodium	Montelukast Sodium	53	18
Clopidogrel	Clopidogrel Bisulfate	51	19
Entresto	Sacubitril/Valsartan	51	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	51	35
Ozempic	Semaglutide	46	suppressed
Glimepiride	Glimepiride	44	15
Trazodone Hcl	Trazodone Hcl	44	suppressed
Baclofen	Baclofen	42	31
Temazepam	Temazepam	42	suppressed
Ammonium Lactate	Ammonium Lactate	41	18
Latanoprost	Latanoprost	39	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	38	23
Telmisartan	Telmisartan	38	11
Novolog Flexpen	Insulin Aspart	37	suppressed
Ibuprofen	Ibuprofen	36	14
Tadalafil	Tadalafil	36	suppressed
Alprazolam	Alprazolam	35	suppressed
Atenolol	Atenolol	35	12
Jardiance	Empagliflozin	35	13
Naproxen	Naproxen	34	18
Meclizine Hcl	Meclizine Hcl	33	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	22
Finasteride	Finasteride	32	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	31	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	31	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	13
Warfarin Sodium	Warfarin Sodium	28	suppressed
Folic Acid	Folic Acid	27	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	27	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	26	24
Enalapril Maleate	Enalapril Maleate	26	suppressed
Glipizide Er	Glipizide	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	22
Bumetanide	Bumetanide	25	suppressed
Meloxicam	Meloxicam	25	11
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	16
Hydrocortisone	Hydrocortisone	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Atrovent Hfa	Ipratropium Bromide	20	suppressed
Ketoconazole	Ketoconazole	20	12
Levemir Flexpen	Insulin Detemir	20	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Prednisone	Prednisone	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Vascepa	Icosapent Ethyl	18	suppressed
Brilinta	Ticagrelor	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Gemtesa	Vibegron	17	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Amoxicillin	Amoxicillin	16	14
Benzonatate	Benzonatate	16	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	16	suppressed
Irbesartan	Irbesartan	15	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Mupirocin	Mupirocin	14	12
Brimonidine Tartrate	Brimonidine Tartrate	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Cefdinir	Cefdinir	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Lactulose	Lactulose	12	suppressed
Levemir	Insulin Detemir	12	suppressed
Methylprednisolone	Methylprednisolone	12	11
Ranolazine Er	Ranolazine	12	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Potassium Chloride	Potassium Chloride	11	suppressed
Procto-Med Hc	Hydrocortisone	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error